Overview

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
Phase:
PHASE1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
orforglipron